Absci (NASDAQ:ABSI – Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.05), Zacks reports. Absci had a negative net margin of 2,321.56% and a negative return on equity of 45.94%. The company had revenue of $1.70 million for the quarter, compared to analysts’ expectations of $1.77 million. During the same quarter last year, the business posted ($0.24) EPS.
Absci Stock Down 1.0 %
NASDAQ ABSI traded down $0.03 during trading hours on Thursday, reaching $3.11. 424,110 shares of the company’s stock traded hands, compared to its average volume of 1,321,264. Absci has a 52-week low of $1.29 and a 52-week high of $6.72. The firm has a 50-day simple moving average of $3.96 and a 200 day simple moving average of $4.08. The firm has a market cap of $353.17 million, a PE ratio of -3.38 and a beta of 2.18. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.49 and a quick ratio of 6.49.
Analyst Upgrades and Downgrades
ABSI has been the topic of several research reports. HC Wainwright reissued a “buy” rating and set a $7.00 price target on shares of Absci in a research note on Wednesday. Guggenheim began coverage on shares of Absci in a research report on Wednesday, October 2nd. They set a “buy” rating and a $10.00 price target for the company. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Absci currently has a consensus rating of “Buy” and an average target price of $8.67.
About Absci
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit.
Featured Stories
- Five stocks we like better than Absci
- Consumer Discretionary Stocks Explained
- Mouse Rising: The Iger Investment Pays Off for Disney Investors
- Stock Sentiment Analysis: How it Works
- Can CAVA Stock Be the Next Chipotle? Earnings Can Help
- How to Find Undervalued Stocks
- Occidental Petroleum Hits New Low: Will Buffett Take the Bait?
Receive News & Ratings for Absci Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Absci and related companies with MarketBeat.com's FREE daily email newsletter.
